Haemonetics Corporation
As of Oct 22, 2026, Haemonetics is in Stage 2, the uptrend phase, now in week 17 (since Jun 24, 2026). It closed at $116.16, 4.8% below its 52-week high and above its 200-day average, which is rising.
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care
Is HAE early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
HAE among Medical Devices4th of 141 by relative strength
All 141 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | TXG | Stage 2 · wk 48 | 99 | −7.8% |
| 2 | RCEL | Stage 2 · wk 13 | 98 | +40.8% |
| 3 | BFLY | Stage 2 · wk 26 | 98 | −26.0% |
| 4 | HAE | Stage 2 · wk 17 | 96 | +8.7% |
| 5 | GKOS | Stage 2 · wk 25 | 96 | +15.1% |
| 6 | AXGN | Stage 3 · wk 2 | 95 | −15.3% |
| 7 | NEOG | Stage 2 · wk 14 | 95 | −11.7% |
| 8 | BVS | Stage 2 · wk 15 | 95 | +10.5% |
Haemonetics: quick answers
What stage is Haemonetics in?
As of Oct 22, 2026, Haemonetics (HAE) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 24, 2026 and is in week 17. What the four stages mean
Is Haemonetics in an uptrend?
Yes. Haemonetics is in a Stage 2 uptrend. It trades 49.9% above its 200-day average, which is rising.
How far is Haemonetics from its 52-week high?
Haemonetics closed at $116.16 on Oct 22, 2026, 4.8% below its 52-week high of $122.06. Its 52-week low is $49.44.
How has Haemonetics performed over the past year?
As of Oct 22, 2026, Haemonetics is up 126.9% over the past year and up 45.2% so far in 2026.
Which sector and industry is Haemonetics in?
Haemonetics is in the Medical Devices industry, part of the Health Care sector.
About this companyHealth Care· Medical Devices
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.